预约演示
Actuate Therapeutics Announces Poster Presentations at the 2023 ASCO Annual Meeting
2023-05-30
临床2期ASCO会议
Actuate Therapeutics Announces Poster Presentations at the 2023 ASCO Annual Meeting
CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023, in Chicago, Illinois.
The abstracts are currently available on the ASCO meeting website. The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.
Poster Presentation Details:
In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.
Presentation Type: Poster Presentation
Date/Time: Saturday, June 3, 2023, 8:00 AM - 11:00 AM
Presenter: Joseph McDermott, Lantern Pharma Inc., Dallas TX
Abstract Number: 3079
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitorglycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).
Presentation Type: Online Publication
Presenter: Dr. Devalingam Mahalingam, Northwestern University, Chicago, IL
Abstract Number: e16289
Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
Presentation Type: Online Publication
Presenter: Taylor Weiskittel, Mayo Clinic, Rochester, MN
Abstract Number: e14555
GSK-3 inhibitorGSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.
Presentation Type: Online Publication
Presenter: Dr. Wafik S. El-Deiry, Brown University, Providence, RI
Abstract Number: e15138
Actuate is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitorGSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
CONTACT:
Public Relations Dept.,
+1 (847) 986-4190
info@actuatetherapeutics.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。